文献速递心力衰竭与心肌病

CDR132L改善慢性心力衰竭大动物模型的收缩与舒张功能

CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure.
PubMed 文献 · Eur Heart J · 2021-01-01

该研究在猪心肌梗死后慢性心衰模型中,于梗死后1个月开始每月静脉给予CDR132L,持续3或5个月,采用盲法随机安慰剂对照设计。结果显示治疗耐受良好,组织暴露充分,并显著改善心脏功能、逆转心脏重构,收缩与舒张功能均获改善。

要点

  • CDR132L在猪慢性心梗后心衰模型中耐受良好,组织暴露充分。
  • 每月重复给药显著改善心脏功能并逆转心脏重构。
  • 除收缩功能恢复外,舒张功能亦获改善。

核心结论

  • 每月重复给予CDR132L安全且能提供临床相关暴露与治疗疗效。
  • CDR132L应作为慢性心力衰竭广泛领域的治疗方向进行探索。

研究设计与样本

  • 研究采用生长缓慢的猪,行左前降支闭塞90分钟后 reperfusion,建立心梗后慢性心衰模型。
  • 动物随机分组,于心梗后1个月开始治疗,每月静脉给予CDR132L,持续3或5个月,采用盲法随机安慰剂对照设计。
  • 疗效通过系列磁共振成像、血流动力学和生物标志物分析评估。

主要发现

  • 治疗组组织暴露充分且CDR132L耐受良好。
  • CDR132L治疗总体显著改善心脏功能并逆转心脏重构。
  • 在该慢性心衰模型中,除收缩功能恢复外,舒张功能也得到改善。

临床怎么用

  • CDR132L每月静脉给药在慢性心梗后心衰模型中显示安全性和疗效,支持进一步临床探索。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Cardiac miR-132 activation leads to adverse remodelling and pathological hypertrophy. CDR132L is a synthetic lead-optimized oligonucleotide inhibitor with proven preclinical efficacy and safety in heart failure (HF) early after myocardial infarction (MI), and recently completed clinical evaluation in a Phase 1b study (NCT04045405). The aim of the current study was to assess safety and efficacy of CDR132L in a clinically relevant large animal (pig) model of chronic heart failure following MI. METHODS AND RESULTS: In a chronic model of post-MI HF, slow-growing pigs underwent 90 min left anterior descending artery occlusion followed by reperfusion. Animals were randomized and treatment started 1-month post-MI. Monthly intravenous (IV) treatments of CDR132L over 3 or 5 months (3× or 5×) were applied in a blinded randomized placebo-controlled fashion. Efficacy was evaluated based on serial magnetic resonance imaging, haemodynamic, and biomarker analyses. The treatment regime provided sufficient tissue exposure and CDR132L was well tolerated. Overall, CDR132L treatment significantly improved cardiac function and reversed cardiac remodelling. In addition to the systolic recovery, diastolic function was also ameliorated in this chronic model of HF. CONCLUSION: Monthly repeated dosing of CDR132L is safe and adequate to provide clinically relevant exposure and therapeutic efficacy in a model of chronic post-MI HF. CDR132L thus should be explored as treatment for the broad area of chronic heart failure.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Batkai S, Genschel C, Viereck J, et al. CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. Eur Heart J. 2021. PMID: 33089304. doi:10.1093/eurheartj/ehaa791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。